Supplemental material
Current Medical Research and Opinion
Volume 39, 2023 - Issue 7
Psychiatry
Safety and efficacy of aripiprazole 2-month ready-to-use 960 mg: secondary analysis of outcomes in adult patients with bipolar I disorder in a randomized, open-label, parallel-arm, pivotal study
Roger S. McIntyrea University of Toronto, Toronto, Canada;b Brain and Cognition Discovery Foundation, Toronto, Canada
https://orcid.org/0000-0003-4733-2523
https://orcid.org/0000-0003-4733-2523, Pedro Suchc H. Lundbeck A/S, Valby, Denmarkhttps://orcid.org/0000-0003-1905-1142
https://orcid.org/0000-0003-1905-1142, Murat Yildirimc H. Lundbeck A/S, Valby, Denmarkhttps://orcid.org/0000-0001-6192-1047
https://orcid.org/0000-0001-6192-1047, Jessica Madera-McDonoughd Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, NJ, USAhttps://orcid.org/0000-0003-2887-7480
https://orcid.org/0000-0003-2887-7480, Zhen Zhangd Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, NJ, USAhttps://orcid.org/0000-0001-8448-5663
https://orcid.org/0000-0001-8448-5663, Frank Larsenc H. Lundbeck A/S, Valby, Denmarkhttps://orcid.org/0000-0002-8318-1681
https://orcid.org/0000-0002-8318-1681 & Matthew Harlind Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, NJ, USACorrespondence[email protected]
https://orcid.org/0000-0001-7087-2734
https://orcid.org/0000-0001-7087-2734 show all